

Abrar K Thabit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2571710/publications.pdf>

Version: 2024-02-01

44
papers

815
citations

759055

12
h-index

526166

27
g-index

47
all docs

47
docs citations

47
times ranked

1106
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibiotic penetration into bone and joints: An updated review. <i>International Journal of Infectious Diseases</i> , 2019, 81, 128-136.	1.5	192
2	Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 159-177.	0.9	152
3	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2533-2541.	1.3	48
4	Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 535-541.	1.1	42
5	Antibacterial Efficacy of Eravacycline <i>In Vivo</i> against Gram-Positive and Gram-Negative Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5001-5005.	1.4	42
6	Assessment of <i>Clostridium difficile</i> Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 215-218.	1.0	26
7	Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in a Child with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5627-5630.	1.4	23
8	Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure <i>In Vivo</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5072-5075.	1.4	22
9	Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in <i>Clostridium difficile</i> infection. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 205-208.	1.1	21
10	Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 727-732.	1.1	18
11	Antibiotics in the Biliary Tract: A Review of the Pharmacokinetics and Clinical Outcomes of Antibiotics Penetrating the Bile and Gallbladder Wall. <i>Pharmacotherapy</i> , 2020, 40, 672-691.	1.2	18
12	The Pharmacodynamics of Prolonged Infusion β -Lactams for the Treatment of <i>Pseudomonas aeruginosa</i> Infections: A Systematic Review. <i>Clinical Therapeutics</i> , 2019, 41, 2397-2415.e8.	1.1	17
13	Effect of Simvastatin and Atorvastatin on Serum Vitamin D and Bone Mineral Density in Hypercholesterolemic Patients: A Cross-Sectional Study. <i>Journal of Osteoporosis</i> , 2014, 2014, 1-9.	0.1	14
14	Clinical impact of pharmacist-directed antimicrobial stewardship guidance following blood culture rapid diagnostic testing. <i>Journal of Hospital Infection</i> , 2020, 106, 436-446.	1.4	14
15	A pilot study to assess bacterial and toxin reduction in patients with <i>Clostridium difficile</i> infection given fidaxomicin or vancomycin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016, 15, 22.	1.7	13
16	Antibiotic use and duration in association with <i>Clostridioides difficile</i> infection in a tertiary academic medical center: A retrospective case-control study. <i>Anaerobe</i> , 2019, 59, 126-130.	1.0	10
17	Incidence of <i>Clostridioides difficile</i> infection at a Saudi Tertiary Academic Medical Center and compliance with IDSA/SHEA, ACG, and ESCMID guidelines for treatment over a 10-year period. <i>Journal of Infection and Public Health</i> , 2020, 13, 1156-1160.	1.9	10
18	Lack of correlation of <i>Brucella</i> antibody titers with clinical outcomes and culture positivity of brucellosis. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2021, 7, 5.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, e47-e54.	0.5	9
20	Development of a Novel Pharmaceutical Formula of Nanoparticle Lipid Carriers of Gentamicin/Tocopherol and In Vivo Assessment of the Antioxidant Protective Effect of Tocopherol in Gentamicin-Induced Nephrotoxicity. <i>Antibiotics</i> , 2019, 8, 234.	1.5	9
21	Systematic review and meta-analysis of the safety of erythromycin compared to clarithromycin in adults and adolescents with pneumonia. <i>Journal of Chemotherapy</i> , 2020, 32, 1-6.	0.7	9
22	Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation. <i>Italian Journal of Pediatrics</i> , 2021, 47, 167.	1.0	8
23	Prevalence, patient characteristics and outcomes of a novel piperacillin/tazobactam-resistant, pan- β -lactam-susceptible phenotype in Enterobacteriaceae : implications for selective reporting. <i>Clinical Microbiology and Infection</i> , 2017, 23, 581-582.	2.8	7
24	Impact of combining vancomycin with piperacillin/tazobactam or with meropenem on vancomycin-induced nephrotoxicity. <i>Internal and Emergency Medicine</i> , 2021, 16, 975-979.	1.0	7
25	Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. <i>Journal of Pharmacy Practice</i> , 2017, 30, 593-599.	0.5	6
26	Comparison of three current Clostridioides difficile infection guidelines: IDSA/SHEA, ESCMID, and ACG guidelines. <i>Infection</i> , 2019, 47, 899-909.	2.3	6
27	Ceftriaxone use in brucellosis: A case series. <i>IDCases</i> , 2019, 18, e00633.	0.4	6
28	Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa : Implications for Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0120421.	1.4	6
29	Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile Infection. <i>Infectious Diseases: Research and Treatment</i> , 2015, 8, IDRT.S23079.	0.7	5
30	Efficacy of Empiric Antibiotic Coverage in Community-Acquired Pneumonia Associated with Each Atypical Bacteria: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4321.	1.0	5
31	Dual versus triple therapy for uncomplicated brucellosis: A retrospective cohort study. <i>Journal of Infection in Developing Countries</i> , 2020, 14, 1380-1386.	0.5	5
32	Pursuing postgraduate pharmacy training in the United States for international pharmacy graduates: Approaches, current status, challenges, and future perspectives. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 224-233.	0.5	5
33	An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes. <i>Infection and Drug Resistance</i> , 2016, Volume 9, 143-148.	1.1	4
34	Association of healthcare exposure with acquisition of different Clostridium difficile strain types in patients with recurrent infection or colonization after clinical resolution of initial infection. <i>Journal of Hospital Infection</i> , 2016, 92, 167-172.	1.4	4
35	Antibiotic utilization within 18 community hospitals in the United States: A 5-year analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 403-408.	0.9	4
36	Characteristics of patients infected with Clostridioides difficile at a Saudi Tertiary Academic Medical Center and assessment of antibiotic duration. <i>Gut Pathogens</i> , 2021, 13, 10.	1.6	4

#	ARTICLE	IF	CITATIONS
37	<i>In Vitro</i> Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> with and without Prior Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 222-228.	1.4	3
38	Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, e55-e63.	0.5	3
39	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Using the ERACE-PA Global Surveillance Program. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab617.	0.4	3
40	COVID-19 vaccine hesitancy and acceptance among the public in the Gulf Cooperation Council countries: A review of the literature. <i>Human Vaccines and Immunotherapeutics</i> , 0, , .	1.4	3
41	When antibiotics experts say no to antibiotics. <i>Germs</i> , 2020, 10, 380-384.	0.5	2
42	Clinical use comparison of a semiautomated PCR with fluorescent ribotyping for typing of <i>Clostridium difficile</i> . <i>Archives of Microbiology</i> , 2017, 199, 317-323.	1.0	0
43	422. Brucellosis Regimens Comparison in a Saudi Tertiary Academic Medical Center. <i>Open Forum Infectious Diseases</i> , 2018, 5, S160-S161.	0.4	0
44	Impact of Combining Vancomycin with Proton Pump inhibitors on the Incidence of Acute Kidney Injury. <i>Basic and Clinical Pharmacology and Toxicology</i> , 0, , .	1.2	0